Le Lézard
Classified in: Health
Subjects: TDS, FVT

Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018

SAN DIEGO, July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9th, 2018 at 11:00 a.m. ET in the London Room at the InterContinental Boston Hotel in Boston, MA.  The presentation will be broadcast via a live webcast and an archive of the presentation will be available for 365 days following the event.  The webcast can be accessed by clicking on the following link: http://wsw.com/webcast/canaccord30/immy/.  The Investor Relations section of the Imprimis website will have a link to the webcast as well, which can be found by clicking here.  Mark and Chief Financial Officer, Andrew Boll, will be hosting one-on-one meetings at the conference and attendees can contact their Canaccord representative to arrange a meeting.

Imprimis Pharmaceuticals Logo (PRNewsFoto/Imprimis Pharmaceuticals)


Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a rapidly growing commercial-stage pharmaceutical company based in San Diego, California.  In addition to owning the nation's leading ophthalmology pharmaceutical compounding business, ImprimisRx, the Company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals and Melt Pharmaceuticals, companies originally founded as subsidiaries of Imprimis.  The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface and Melt.  For more information about Imprimis, please visit the Investor Relations section of the corporate website by clicking here.


This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

No Imprimis compounded formulation is FDA-approved. Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.


Investor Contact:
Jon Patton

SOURCE Imprimis Pharmaceuticals, Inc.

These press releases may also interest you

at 03:05
SAN DIEGO, Oct. 22, 2018 /PRNewswire-PRWeb/ -- Achieve TMS/TMS Center of Alaska, the nation's largest and most experienced provider of deep TMS (transcranial magnetic simulation) for the treatment of depression is now offering TMS treatment for...

at 03:00
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today the commercial launch of an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion...

at 03:00
Biohaven Pharmaceutical Holding Company Ltd. , a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that the first participant was dosed with BHV-3500, a third generation calcitonin gene-related...

at 03:00
OssDsign AB, the Swedish designer, manufacturer and distributor of regenerative implants for cranial and facial reconstruction, today announced that it has received 510(k) clearance by the US FDA for marketing and sale of its...

at 03:00
High Hampton Holdings Corp. ("High Hampton" or the "Company") is pleased to announce that a new independent director has been appointed to its board to strengthen the Company's leadership with an additional seasoned executive...

at 03:00
NEW YORK, Oct. 22, 2018 /PRNewswire-PRWeb/ -- Manhattan Mental Health Counseling, a psychotherapy private practice in NYC that accepts insurance, has issued a warning about the potential health risks of using - and overusing - social media. There...

News published on 18 july 2018 at 07:30 and distributed by: